Literature DB >> 22470745

Gynaecomastia associated with highly active antiretroviral therapy (HAART).

Debra Meerkotter1.   

Abstract

There is a global Acquired Immune Deficiency Syndrome (AIDS) epidemic. It is estimated that the total number of people living with Human Immune deficiency Virus (HIV) is 33.2 million in the year 2007. An estimated 2.1 million people died from AIDS in 2007. As highly active antiretroviral therapy (HAART) becomes more widely used, the side effects of this regime are becoming more evident in clinical practice. We present 2 cases that demonstrate the association of HAART and gynaecomastia. Imaging features of gynaecomastia and the differential for these changes will be reviewed. Proposed mechanisms for the pathogenesis of gynaecomastia will be discussed. Possible therapeutic options will also be briefly considered.

Entities:  

Keywords:  AIDS; Gynaecomastia imaging; HAART; HIV; highly active antiretroviral therapy

Year:  2010        PMID: 22470745      PMCID: PMC3303362          DOI: 10.3941/jrcr.v4i7.452

Source DB:  PubMed          Journal:  J Radiol Case Rep        ISSN: 1943-0922


  10 in total

Review 1.  Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: four cases and a review of the literature.

Authors:  O Benveniste; A Simon; S Herson
Journal:  Clin Infect Dis       Date:  2001-08-10       Impact factor: 9.079

2.  Bilateral gynecomastia with microcalcifications in an HIV infected hemophilia A patient after HAART.

Authors:  A N Chalazonitis; G D Theodossiades; E Nomikou; V Tsevrenis; G Zografos
Journal:  JBR-BTR       Date:  2006 Nov-Dec

3.  Incidence of gynecomastia in men infected with HIV and treated with highly active antiretroviral therapy.

Authors:  L Piroth; M Grappin; J M Petit; M Buisson; M Duong; P Chavanet; H Portier
Journal:  Scand J Infect Dis       Date:  2001

Review 4.  Gynecomastia: its features, and when and how to treat it.

Authors:  Shirley A Bembo; Harold E Carlson
Journal:  Cleve Clin J Med       Date:  2004-06       Impact factor: 2.321

Review 5.  Pathology of the breast associated with HIV/AIDS.

Authors:  Liron Pantanowitz; James L Connolly
Journal:  Breast J       Date:  2002 Jul-Aug       Impact factor: 2.431

Review 6.  Efavirenz-associated gynecomastia: report of five cases and review of the literature.

Authors:  Francisco Jover; José M Cuadrado; Pablo Roig; Marta Rodríguez; Lucio Andreu; Jaime Merino
Journal:  Breast J       Date:  2004 May-Jun       Impact factor: 2.431

7.  Gynecomastia in HIV-infected patients receiving antiretroviral therapy.

Authors:  Teresa García-Benayas; Francisco Blanco; Luz Martín-Carbonero; Eulalia Valencia; Ana Barrios; Juan González-Lahoz; Vincent Soriano
Journal:  AIDS Res Hum Retroviruses       Date:  2003-09       Impact factor: 2.205

8.  Tamoxifen in antiretroviral-associated gynaecomastia.

Authors:  Stephen Kegg; Richard Lau
Journal:  Int J STD AIDS       Date:  2002-08       Impact factor: 1.359

Review 9.  Gynecomastia.

Authors:  Harmeet Singh Narula; Harold E Carlson
Journal:  Endocrinol Metab Clin North Am       Date:  2007-06       Impact factor: 4.741

10.  Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study.

Authors:  Alejandra Biglia; Jose L Blanco; Esteban Martínez; Pere Domingo; Roser Casamitjana; María Sambeat; Ana Milinkovic; Mercedes Garcia; Montserrat Laguno; Agathe Leon; Maria Larrousse; Montserrat Lonca; Josep Mallolas; Jose M Gatell
Journal:  Clin Infect Dis       Date:  2004-10-25       Impact factor: 9.079

  10 in total
  2 in total

1.  Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.

Authors:  Beatriz Larru; Jessica Eby; Elizabeth D Lowenthal
Journal:  Pediatric Health Med Ther       Date:  2014-05-29

2.  Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report.

Authors:  Mette S van Ramshorst; Magdeline Kekana; Helen E Struthers; James A McIntyre; Remco P H Peters
Journal:  BMC Pediatr       Date:  2013-08-13       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.